Cargando...
Tranilast blunts the hypertrophic and fibrotic response to increased afterload independent of cardiomyocyte transient receptor potential vanilloid 2 channels
Tranilast is clinically indicated for the treatment of allergic disorders and is also a non-selective blocker of the Transient Receptor Potential Vanilloid 2 (TRPV2) channel. Prior studies have found that it has protective effects in various animal models of cardiac disease. Our laboratory has found...
Guardado en:
| Publicado en: | J Cardiovasc Pharmacol |
|---|---|
| Autores principales: | , , , , , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2018
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6033629/ https://ncbi.nlm.nih.gov/pubmed/29688911 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FJC.0000000000000588 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|